AnaptysBio GAAP EPS of $0.11 misses by $0.28, revenue of $30.27M misses by $3.19M
AnaptysBio reported Q1 GAAP EPS of $0.11, missing estimates by $0.28, and revenue of $30.27M, missing by $3.19M. Revenue fell 60.3% year-over-year, according to the company.
How this was made
The 30-second read
Why it matters
The earnings shortfall is likely to trigger short‑term selling pressure, though longer‑term valuation will depend on pipeline milestones.
Market read
Micro‑cap biotech earnings miss, relevant for short‑term traders and biotech sector watchers.
What to watch
Potential upcoming clinical trial data or partnership announcements could offset the earnings disappointment.
Background
AnaptysBio released its Q1 2026 GAAP earnings, reporting a significant miss on both EPS and revenue.
Ticker impact
Q1 GAAP EPS of $0.11 missed expectations by $0.28 and revenue of $30.27M missed by $3.19M, marking the first public disclosure of the quarter's results.
downward pressure as investors price in the earnings shortfall
Both EPS and revenue fell short of expectations, a clear negative catalyst for a micro‑cap biotech.
Market effects
Biotech sector may see modest pullback as earnings miss adds to sector risk sentiment.
US biotech stocks could see slight weakness in late‑day trading.
Limited to investors tracking small‑cap biotech earnings.
Counterpoint
If the miss is viewed as a temporary setback and pipeline progress remains strong, the stock could be a buying opportunity at lower levels.
Key entities
- companyAnaptysBio, Inc.
US‑listed biotech company (NASDAQ: ANAB) reporting Q1 results.

